LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1476 | 544 | 3694 | 0.1474 | -0.4204 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 72 | hr | 1476 | 597 | 3694 | 0.1616 | -0.3968 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 1476 | 630 | 3694 | 0.1707 | -0.3816 |
| SK-BR-3 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 659 | 3694 | 0.1786 | -0.3685 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 662 | 3694 | 0.1794 | -0.3671 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 1476 | 688 | 3694 | 0.1864 | -0.3554 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 732 | 3694 | 0.1983 | -0.3356 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 757 | 3694 | 0.2051 | -0.3243 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 765 | 3694 | 0.2073 | -0.3207 |
| SK-BR-3 | AT-7519 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 788 | 3694 | 0.2133 | -0.3106 |
| SK-BR-3 | AZD 5438 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 807 | 3694 | 0.2186 | -0.3017 |
| SK-BR-3 | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 809 | 3694 | 0.2192 | -0.3008 |
| SK-BR-3 | SNS-032 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 823 | 3694 | 0.2230 | -0.2945 |
| MCF7 | AZD 5438 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 381 | 4156 | 0.0917 | -0.2925 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP5 | 72 | hr | 1476 | 829 | 3694 | 0.2245 | -0.2920 |
| MCF7 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 383 | 4156 | 0.0922 | -0.2917 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP6 | 72 | hr | 1476 | 834 | 3694 | 0.2258 | -0.2899 |
| BT-20 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 545 | 5505 | 0.0991 | -0.2890 |
| SK-BR-3 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 843 | 3694 | 0.2282 | -0.2858 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 843 | 3694 | 0.2283 | -0.2857 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 846 | 3694 | 0.2292 | -0.2842 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1235 | 408 | 4156 | 0.0982 | -0.2833 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 852 | 3694 | 0.2306 | -0.2817 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 856 | 3694 | 0.2319 | -0.2796 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 1235 | 420 | 4156 | 0.1011 | -0.2791 |